Results 181 to 190 of about 120,942 (241)

Circadian Phase-Dependent Modulation of cGMP-Gated Channels of Cone Photoreceptors by Dopamine and D2 Agonist [PDF]

, 2003
Gladys Y.‐P. Ko, Michael L. Ko, Stuart E. Dryer   +2 more
openalex   +1 more source

Treatment of social phobia with the dopamine agonist pergolide

, 2000
Gerardo Villarreal, Mike Johnson, Robert N. Rubey, R. Bruce Lydiard, James C. Ballanger   +4 more
openalex   +1 more source

Feedback inhibition of dopamine synthesis by continuous administration of dopamine agonists

, 2000
Shin-ichi Iwata, Masahiro Nomoto, Shun Kaseda, Takeo Fududa   +3 more
openalex   +1 more source

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson's Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better? [PDF]

Clin Park Relat Disord
Wu HF, Yu ELM, Sheng B, Wong KK, Au Yeung M, Wong WT, Kwan HH, Ng LP, Cheung CH, Lam YL, Chan YK.   +10 more
europepmc   +1 more source

Dihydrexidine — The First Full Dopamine D₁ Receptor Agonist [PDF]

, 2004
Peter Salmi, Ruben Isacson, Björn Kull
openalex   +1 more source

Adrogolide HCl (ABT‐431; DAS‐431), a Prodrug of the Dopamine D₁ Receptor Agonist, A‐86929: Preclinical Pharmacology and Clinical Data

, 2001
William J. Giardina, Michael Williams
openalex   +1 more source

Dopamine agonist resistant prolactinomas: any alternative medical treatment? [PDF]

Pituitary, 2020
Souteiro P, Karavitaki N.
europepmc   +1 more source

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease. [PDF]

Neuroimage Clin, 2020
van der Vegt JPM, Hulme OJ, Madsen KH, Buhmann C, Bloem BR, Münchau A, Helmich RC, Siebner HR.   +7 more
europepmc   +1 more source